PPARG and myeloid sarcoma: The PPARγ antagonist, 2-chloro-5-nitro-N-phenyl-benzamide(GW9662), prevented the neuroprotective effect of pioglitazone [48],suggesting the involvement of PPARγ-dependent mechanisms in theregulation of inflammation and new therapeutic avenue for the treatment of MS.